Insectivorous toxin Campylobacter selective isolation medium mCCDA Clear HT
252794 (pack of 20) and 252950 (pack of 100)
This is a new selective isolation medium for Campylobacter, the most common cause of food poisoning! Delivered from our domestic factory!
What is BD(TM) mCCDA Clear HT? Based on the selective isolation medium for Campylobacter, mCCDA (modified Charcoal Cefoperazone Desoxycholate Agar), this product ensures high visibility by forming purple colonies on a transparent medium through a patented manufacturing process. Additionally, it suppresses the growth of contaminants with high selectivity. Features This product makes it easy to identify colonies, improving the efficiency of the tester's work. Furthermore, it reduces the likelihood of overlooking the characteristic difficult-to-identify colonies of Campylobacter (droplet-like colonies that appear thin and spread out), which is particularly useful in facilities lacking testers with extensive knowledge and experience in microbiological testing.
Inquire About This Product
basic information
【Packaging Unit】 252794 BD(TM) mCCDA Clear HT Agar Medium 20 sheets 252950 BD(TM) mCCDA Clear HT Agar Medium 100 sheets *For more details, please refer to the catalog. Feel free to contact us.
Price range
P1
Delivery Time
P2
Applications/Examples of results
This product is used as a selective isolation medium for Campylobacter, which is particularly abundant in chicken and beef liver. Traditional Campylobacter selective isolation media are red or black due to the presence of blood or activated charcoal, but this product ensures high visibility by forming purple colonies on a transparent medium. Additionally, it effectively suppresses the growth of contaminants with its high selectivity.
Line up（2）
| Model number | overview |
|---|---|
| 252794 | BD mCCDA Clear HT Agar Medium 20 sheets |
| 252950 | BD mCCDA Clear HT Agar Medium 100 sheets |
catalog（1）
Download All Catalogs
Company information
BD Japan is the Japanese subsidiary of BD, one of the world's leading medical device and medtech companies headquartered in New Jersey, USA. BD aims to lead the world in medical technology, seeking new insights in the healthcare field and improving the quality of diagnosis and treatment, with the purpose of realizing "The future of healthcare for all(TM)." By developing innovative technologies and services related to patient treatment and healthcare processes, BD supports those working on the front lines of healthcare. With approximately 77,000 employees worldwide, BD staff support researchers in the development of next-generation diagnostic and therapeutic methods and strive daily to enhance the safety of healthcare professionals and the efficiency of medical practices in clinical settings. By partnering with healthcare institutions in countries around the world and addressing global priority issues, BD contributes to improving healthcare outcomes, reducing costs, increasing efficiency, enhancing safety, and promoting access to healthcare through close collaboration with its customers, the healthcare institutions.
